REEV doubles Neuro-Integration Program to six clinical partners

REEV added Jefferson Moss-Magee Rehabilitation, Community Health System and DHR Health to its Neuro-Integration Program, bringing the total to six clinical partners in four months. The expansion widens the stroke rehab network supporting DREEVEN, REEV’s investigational AI-powered robotic knee orthosis, ahead of its planned U.S. launch.

Why it matters: - REEV is building the clinical network it needs before DREEVEN can reach stroke survivors at scale. - The expanded partner base increases the number of patients being evaluated for possible use of the AI-powered robotic knee orthosis. - The program also helps generate real-world gait data that could support reimbursement workflows.

What happened: - REEV’s Neuro-Integration Program doubled in four months, rising from its founding partners to six signed clinical partners. - Jefferson Moss-Magee Rehabilitation joined the program. - Community Health System in California’s Central Valley joined the program. - DHR Health in South Texas joined the program. - The announcement was made Sept. 15, 2026. - The expansion extends the program’s reach to the West Coast and South Texas.

The details: - The Neuro-Integration Program is a clinical collaboration initiative focused on stroke rehabilitation organizations. - The program is designed to prepare for the commercial introduction of DREEVEN, REEV’s AI-powered robotic knee orthosis. - DREEVEN is intended to help stroke survivors regain safe, independent mobility for daily life. - Jefferson Moss-Magee Rehabilitation is a U.S. News & World Report top 10 rehabilitation facility. - Dr. Alberto Esquenazi, MD, Department Chair and Chief Clinical Officer, leads Jefferson Moss-Magee Rehabilitation’s participation. - Community Health System’s outpatient rehabilitation program is led by Julie Evans, OTR/L, CHT, Manager, Outpatient Rehabilitation. - DHR Health’s participation is overseen by Michael Auer, PT, DPT, C/NDT, Director of the Neuro Therapy Institute and Cardiac Rehabilitation. - NIP partner facilities collectively serve about 1,000 stroke patients who are expected to be potential DREEVEN candidates at launch. - More than 2,000 patients have been assessed through SENSE, REEV’s gait analysis system. - SENSE helps clinicians identify potential DREEVEN candidates. - REEV says the dataset being built through SENSE is among the largest real-world gait rehabilitation datasets and should help support reimbursement workflows. - REEV is in active discussions with 25 major hospital systems across 20 U.S. states. - Those hospital systems represent more than 5,000 stroke survivors who may benefit from DREEVEN. - DREEVEN is an investigational device and has not been cleared or approved for commercial sale in the United States. - REEV has offices in Toulouse, France, and Boston, Massachusetts. - REEV’s portfolio includes REEV SENSE, a HIPAA-compliant, FDA-cleared gait analysis system, and DREEVEN, a prescription-based intelligent robotic knee brace currently in clinical trials.

Between the lines: - The partner additions suggest REEV is moving from product development toward building the clinical infrastructure needed for eventual commercialization. - The focus on leading rehab centers and health systems signals an effort to strengthen credibility with clinicians, payers and hospital buyers. - The company’s emphasis on assessment data suggests it is trying to support both patient selection and future reimbursement. - Julie Evans said Community Health System sees the partnership as a way to bring innovation to gait rehabilitation and help stroke survivors regain mobility. - Michael E. Auer said DHR Health is using REEV SENSE to analyze walking patterns and tailor treatment strategies. - Auer also said DHR Health looks forward to using DREEVEN as another tool for targeted gait training. - Amaury Ciurana, REEV’s CEO and co-founder, said the growth reflects demand for better options for stroke survivors and a need to restore daily mobility.

What's next: - REEV will keep expanding the Neuro-Integration Program as it prepares for DREEVEN’s eventual market entry. - The company’s current hospital discussions could broaden the clinical network beyond the six signed partners. - REEV will continue gathering gait-assessment data through SENSE while DREEVEN remains in clinical trials. - The company still needs U.S. clearance or approval before DREEVEN can be sold commercially.

The bottom line: - REEV is using clinical partnerships and real-world gait data to lay the groundwork for a future stroke-rehab product launch.